News

US FDA Approves SyneuRx’s IND Application for a Phase II Clinical Trial for Adult Patients with Treatment-Resistant Depression and Suicidal Symptoms

  • Post author:
  • Post category:News

US FDA Approves SyneuRx’s IND Application for a Phase II Clinical Trial for Adult Patients with Treatment-Resistant Depression and Suicidal Symptoms Press Release Mar 26, 2021      On March 26, 2021, SyneuRx announced…

Continue ReadingUS FDA Approves SyneuRx’s IND Application for a Phase II Clinical Trial for Adult Patients with Treatment-Resistant Depression and Suicidal Symptoms

US FDA Approves SyneuRx’s IND Application for a First-in-Human, Proof of Principle Clinical Trial for Patients with Early and Mild COVID-19

  • Post author:
  • Post category:News

US FDA Approves SyneuRx’s IND Application for a First-in-Human, Proof of Principle Clinical Trial for Patients with Early and Mild COVID-19 Press Release Feb 04, 2021   SyneuRx announced today that…

Continue ReadingUS FDA Approves SyneuRx’s IND Application for a First-in-Human, Proof of Principle Clinical Trial for Patients with Early and Mild COVID-19

First Five Subjects Randomized in SyneuRx’ SND12 Phase IIb/III Study of Clozaben®, a Novel Treatment for Refractory Schizophrenia

  • Post author:
  • Post category:News

First Five Subjects Randomized in SyneuRx’ SND12 Phase IIb/III Study of Clozaben®, a Novel Treatment for Refractory Schizophrenia Press Release May 22, 2017   SyneuRx International (Taiwan) Corp. today announced that the…

Continue ReadingFirst Five Subjects Randomized in SyneuRx’ SND12 Phase IIb/III Study of Clozaben®, a Novel Treatment for Refractory Schizophrenia

First Three Subjects Randomized in SyneuRx’ SND13 Phase IIb/III NaBen© Schizophrenia Trial

  • Post author:
  • Post category:News

First Three Subjects Randomized in SyneuRx’ SND13 Phase IIb/III NaBen© Schizophrenia Trial Press Release May 11, 2017   SyneuRx International (Taiwan) Corp. today announced that the first three subjects have been randomized…

Continue ReadingFirst Three Subjects Randomized in SyneuRx’ SND13 Phase IIb/III NaBen© Schizophrenia Trial

SyneuRx Receives US FDA Breakthrough Therapy Designation for SND12 for the Treatment of Refractory Schizophrenia in Adults

  • Post author:
  • Post category:News

SyneuRx Receives US FDA Breakthrough Therapy Designation for SND12 for the Treatment of Refractory Schizophrenia in Adults Press Release Dec 19, 2015   Taipei, December 19, 2015- SyneuRx International (Taiwan) Corp.,…

Continue ReadingSyneuRx Receives US FDA Breakthrough Therapy Designation for SND12 for the Treatment of Refractory Schizophrenia in Adults